Incyclix Bio, LLC

Incyclix Bio, LLC is a biotechnology company specializing in the development of innovative oncology therapeutics, particularly focused on precision treatments for various cancers through targeted therapeutic strategies. Founded in 2020 in the United States, Incyclix Bio, LLC develops oncology solutions, including its lead product INX-315, a CDK2 inhibitor currently in clinical trials. In April 2026, Incyclix Bio, LLC raised USD 5 million in series B funding from Hatteras Venture Partners.  Patrick Roberts serves as the CEO, with a notable partnership with John Bisi in founding the company.

Incyclix Bio focuses on developing innovative oncology therapeutics that target the aberrant proliferation characteristic of various cancers. Their lead product, INX-315, is a selective inhibitor of cyclin-dependent kinase 2 (CDK2) and is currently undergoing clinical trials aimed at treating ovarian, breast, and lung cancers, particularly in patients resistant to existing treatments. The company is positioned to serve healthcare providers and patients, with products tailored for individuals with specific genetic markers, such as CCNE1 amplification. Incyclix Bio's revenue model is based on partnerships and clinical trial agreements, which support the commercialization of INX-315 and other products.

The company engages in business-to-business transactions with healthcare institutions and pharmaceutical partners. Revenue is expected to be generated through successful clinical trial milestones and regulatory approvals, with pricing strategies potentially including direct sales to healthcare facilities and subscription models for access to therapies, though specific pricing details are confidential. In August 2025 Incyclix Bio, LLC raised USD 11. 25 million in series B funding from returning investor Eshelman Ventures.

New investors Eli Lilly and Company, Pharmacosmos A/S, Cape Fear BioCapital and other unspecified investors also participated in the round. The company plans to continue its product development and aims to expand its market presence in North America and Europe, with growth initiatives expected to be supported by the recent funding. The company will use the April 2026 funding to support the clinical development of its lead compound INX-315 for the treatment of advanced and metastatic breast and ovarian cancer.